Sling Therapeutics to Present Data from Phase 2b/3 LIDS Trial of Oral IGF-1R Inhibitor Linsitinib in Thyroid Eye Disease at ASOPRS 57th Annual Fall Scientific Symposium

Sling Therapeutics announced that data from its Phase 2b/3 LIDS trial of linsitinib in adults with moderate to severe active thyroid eye disease will be presented at the ASOPRS 57th Annual Fall Scientific Symposium on October 8–9, 2026. The announcement provides no trial results or additional numerical data.

Analysis

This is a near-term information catalyst, not evidence of clinical or commercial success: the announcement provides no efficacy, safety, or trial-design results. The presentation is scheduled for October 8–9, so any repricing should hinge on the actual dataset and whether it is sufficiently detailed to assess against existing TED treatment options. The key competitive question is whether oral linsitinib can offer a meaningful convenience or tolerability advantage without sacrificing efficacy; oral dosing alone does not establish a durable advantage. Amgen’s Tepezza is the relevant commercial benchmark, but the announcement by itself does not change its outlook. Over the next 1–3 months, follow-up disclosures and regulatory or development guidance matter more than the presentation notice. Over 6–18 months, credible differentiation could pressure incumbent treatment economics or broaden the treated population; weak efficacy, safety concerns, or limited durability would undermine that thesis. With no results and no publicly mapped Sling ticker, there is no supported directional trade today.

Key Decisions for Investors

• Do not trade the announcement as a positive read-through for linsitinib; wait for the October 8–9 presentation and review the underlying data.
• At the event, verify trial design and endpoints, effect size, statistical uncertainty, adverse events, discontinuations, and durability. Treat any company characterization without the supporting dataset as unconfirmed.
• Keep Amgen/Tepezza on watch rather than shorting it: reassess only if linsitinib shows credible efficacy with a meaningful oral-use or safety advantage, and confirm whether the data could realistically alter treatment choice.
• Falsify the emerging-competitor thesis if the full results show weak or uncertain efficacy, clinically relevant tolerability issues, or insufficient follow-up to support durability; absent a favorable dataset, no trade is warranted.